Innopran XL: Advanced Beta-Blocker Therapy for Hypertension Control
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.91 | $57.23 (0%) | 🛒 Add to cart |
| 60 | $1.36 | $114.46 $81.33 (29%) | 🛒 Add to cart |
| 90 | $1.17 | $171.69 $105.43 (39%) | 🛒 Add to cart |
| 120 | $1.08 | $228.93 $129.52 (43%) | 🛒 Add to cart |
| 180 | $0.99 | $343.39 $177.72 (48%) | 🛒 Add to cart |
| 270 | $0.93 | $515.08 $250.01 (51%) | 🛒 Add to cart |
| 360 | $0.90
Best per pill | $686.78 $322.30 (53%) | 🛒 Add to cart |
| Product dosage: 80mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.04 | $61.25 (0%) | 🛒 Add to cart |
| 60 | $1.44 | $122.50 $86.35 (30%) | 🛒 Add to cart |
| 90 | $1.23 | $183.74 $110.45 (40%) | 🛒 Add to cart |
| 120 | $1.12 | $244.99 $134.54 (45%) | 🛒 Add to cart |
| 180 | $1.03 | $367.49 $184.75 (50%) | 🛒 Add to cart |
| 270 | $0.96 | $551.23 $258.04 (53%) | 🛒 Add to cart |
| 360 | $0.91
Best per pill | $734.97 $329.33 (55%) | 🛒 Add to cart |
Similar products
Innopran XL (propranolol hydrochloride) is an extended-release formulation designed for the long-term management of hypertension and certain cardiovascular conditions. As a nonselective beta-adrenergic blocking agent, it offers sustained 24-hour blood pressure control through a single daily dose, enhancing patient adherence and reducing peak-trough fluctuations. Its specialized delivery system ensures consistent plasma concentrations, making it a reliable choice in antihypertensive regimens. Clinicians value its established efficacy profile and predictable pharmacokinetics in diverse patient populations.
Features
- Active ingredient: Propranolol hydrochloride
- Formulation: Extended-release capsules
- Available strengths: 80 mg, 120 mg, 160 mg
- Pharmacologic class: Nonselective beta-blocker
- Mechanism: Competitively blocks beta-1 and beta-2 adrenergic receptors
- Half-life: Approximately 10 hours (extended-release formulation)
- Administration: Oral, once daily
- Bioavailability: Not significantly affected by food
- Specialized delivery: Osmotic controlled-release technology
Benefits
- Provides smooth 24-hour blood pressure control with minimal peak-trough variations
- Reduces cardiovascular morbidity and mortality through effective hypertension management
- Single daily dosing improves medication adherence and quality of life
- Demonstrates proven efficacy in reducing angina episodes and migraine frequency
- Offers cardiovascular protection beyond blood pressure control
- Well-established safety profile with decades of clinical use
Common use
Innopran XL is primarily indicated for the management of hypertension, either as monotherapy or in combination with other antihypertensive agents. It is also used for the prophylaxis of common migraine headaches and management of essential tremor. Off-label uses include treatment of situational anxiety, hyperthyroidism symptoms, and certain types of arrhythmias. The extended-release formulation is particularly valuable for patients requiring stable beta-blockade throughout the 24-hour dosing interval.
Dosage and direction
The recommended initial dosage for hypertension is 80 mg once daily, preferably in the morning. Dosage may be increased to 120 mg or 160 mg once daily based on therapeutic response and tolerability. Maximum recommended dose is 640 mg daily, though most patients respond to doses between 160-320 mg daily. For migraine prophylaxis, initial dose is 80 mg daily divided doses, with maintenance range of 160-240 mg daily. Administration should be consistent with regard to meals, though food does not significantly affect absorption. Capsules must be swallowed whole and not crushed or chewed.
Precautions
Abrupt discontinuation may precipitate angina, myocardial infarction, or ventricular arrhythmias in patients with coronary artery disease. Gradually reduce dosage over 1-2 weeks while monitoring patient closely. Use with caution in patients with compensated heart failure, diabetes mellitus, or thyrotoxicosis. May mask signs of hypoglycemia and hyperthyroidism. Can cause bronchospasm in patients with reactive airway disease. May reduce exercise tolerance and cause cold extremities. Caution advised when administering to elderly patients due to increased sensitivity to beta-blockers.
Contraindications
Bronchial asthma, severe chronic obstructive pulmonary disease, or history of bronchospasm. Cardiogenic shock, overt cardiac failure, severe sinus bradycardia, second- or third-degree AV block, sick sinus syndrome without permanent pacemaker. Hypersensitivity to propranolol or any component of the formulation. Uncompensated congestive heart failure requiring positive inotropic therapy. Severe peripheral arterial circulatory disorders.
Possible side effect
Common (≥1%): Fatigue, dizziness, bradycardia, cold extremities, nausea, diarrhea, sleep disturbances. Less common: Depression, vivid dreams, impotence, Raynaud’s phenomenon, heart failure exacerbation, bronchospasm. Rare: Hallucinations, thrombocytopenic purpura, agranulocytosis, mesenteric arterial thrombosis. Most side effects are dose-dependent and often diminish with continued therapy or dosage adjustment.
Drug interaction
Significant interactions occur with: Calcium channel blockers (additive bradycardia and hypotension), digoxin (increased AV block risk), insulin/oral hypoglycemics (masked hypoglycemia symptoms, altered glucose metabolism), NSAIDs (reduced antihypertensive effect), CYP2D6 inhibitors (quinidine, fluoxetine - increased propranolol levels), warfarin (increased anticoagulant effect), epinephrine (unopposed alpha-adrenergic effects), theophylline (reduced bronchodilator effect).
Missed dose
If a dose is missed, take it as soon as remembered unless it is closer to the time of the next dose. Do not double the dose to make up for a missed dose. If multiple doses are missed, contact healthcare provider before resuming therapy, as dosage adjustment or gradual retitration may be necessary to avoid withdrawal symptoms.
Overdose
Symptoms include severe bradycardia, heart failure, hypotension, bronchospasm, hypoglycemia, and seizures. Management involves gastric lavage if recent ingestion, activated charcoal, and supportive care. Specific treatments include atropine for bradycardia, glucagon for myocardial depression, beta-2 agonists for bronchospasm, and glucose for hypoglycemia. Hemodialysis is not effective due to high protein binding. Continuous cardiac monitoring is essential.
Storage
Store at controlled room temperature 20-25°C (68-77°F). Excursions permitted to 15-30°C (59-86°F). Keep container tightly closed and protect from moisture. Dispense in original container with child-resistant closure. Keep out of reach of children and pets. Do not use if capsules are damaged or show signs of moisture exposure.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Individual patient responses may vary. Healthcare professionals should exercise clinical judgment when prescribing. Patients should not adjust dosage or discontinue medication without consulting their healthcare provider. Full prescribing information should be consulted before initiation of therapy.
Reviews
Clinical studies demonstrate consistent antihypertensive efficacy with 70-80% of patients achieving target blood pressure goals. Long-term extension studies show maintained efficacy over 12-24 months of treatment. Patient satisfaction surveys indicate high adherence rates due to once-daily dosing. Specialist evaluations note particular value in patients requiring smooth 24-hour beta-blockade without significant peak effects. Real-world evidence supports the cardiovascular protective benefits observed in clinical trials.